Accelerate Diagnostics’ Shareholder Decisions at Annual Meeting

Accelerate Diagnostics (AXDX) has issued an announcement.

During the 2024 Annual Meeting, shareholders of the Company made key decisions: they elected nine directors to serve until the next annual meeting, ratified Ernst & Young LLP as their independent accounting firm for the year, and approved an amendment to increase the number of shares available for the 2022 Incentive Plan. The detailed voting results reflected strong support for the elected directors and the ratification of the accounting firm, with a more divided outcome on the plan amendment.

Learn more about AXDX stock on TipRanks’ Stock Analysis page.